TissueAgnostic Cancer Treatments Can US FDAApproved Diagnostics Limit Access
Tissue-Agnostic Cancer Treatments: Can US FDA-Approved Diagnostics Limit Access?
14:13 EDT 17 Jun 2019 |
SCRIP
ASCO official argues postmarket development of diagnostics may restrict patient use once added to the label.
More From BioPortfolio on "Tissue-Agnostic Cancer Treatments: Can US FDA-Approved Diagnostics Limit Access?"